Published mark
Kura Oncology, Inc.
NASDAQ: KURA. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:a0efacbe-524c-4f0c-8c09-118fc6401d00
- SEC CIK
- 0001422143
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 7, 2026
- Newest evidence
- Apr 10, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Troy E. Wilson, Ph.D., J.D.Since Apr 10, 2026
- Chair
- Troy E. WilsonLead independent: Faheem Hasnain
- Independent
- Not published5 directors published
- Published claims
- 332 distinct sources
- Evidence records
- 80 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 8 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Brian Powl seat on Kura Oncology, Inc., effective 2026-04-10.
EffectiveEffective Apr 10, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Scientific Officer | Francis Burrows, Ph.D. | Apr 2026 | current | Source reportedE4 |
| Chief Medical Officer | Mollie Leoni, M.D. | Apr 2026 | current | Source reportedE5 |
| Chief Legal Officer and Secretary | Teresa Bair, J.D. | Apr 2026 | current | Source reportedE6 |
| Chairman, President and Chief Executive Officer | Troy E. Wilson, Ph.D., J.D. | Apr 2026 | current | Source reportedE7 |
| Chief Commercial Officer | Brian Powl | Not captured | unknown | Source reportedE2 |
| Chief Scientific Officer | Francis Burrows | Not captured | unknown | Source reportedE2 |
| Chief Operating Officer | Kathleen Ford | Not captured | unknown | Source reportedE2 |
| Chief Medical Officer | Mollie Leoni | Not captured | unknown | Source reportedE2 |
| Chief Legal Officer and Secretary | Teresa Bair | Not captured | unknown | Source reportedE2 |
| President and Chief Executive Officer | Troy E. Wilson | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence5 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Brian Powl | Independence not published | 2026 | None published | Source reportedE3 |
| Diane Parks | Independence not published | 2019 | Compensation CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Helen Collins | Independence not published | 2021 | Compensation CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Mary T. Szela | Independence not published | 2018 | Audit CommitteeCompensation Committee | Source reportedE3 |
| Michael Vasconcelles | Independence not published | 2026 | Compensation Committee | Source reportedE3 |
| Carol Schafer | Independent | Not published | None published | Source reportedE2 |
| Faheem Hasnain | IndependentLead Independent | Not published | None published | Source reportedE2 |
| Thomas Malley | Independent | Not published | None published | Source reportedE2 |
| Troy E. Wilson | Not independentChair | Not published | President and Chief Executive Officer, chair | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit Committee | Not published | Mary T. Szela, Mary T. Szela | Not described in the published record |
| Compensation Committee | Not published | Diane Parks, Helen Collins, Mary T. Szela, Michael Vasconcelles, Diane Parks, Helen Collins, Mary T. Szela, Michael Vasconcelles | Not described in the published record |
| Nominating and Corporate Governance Committee | Not published | Diane Parks, Helen Collins, Diane Parks, Helen Collins | Not described in the published record |
| President and Chief Executive Officer | Troy E. Wilson | Troy E. Wilson | Not described in the published record |
Committee RecordAudit Committee: Chair not stated; Members Mary T. Szela
Committee AppointmentMary T. Szela: member, Audit Committee
Committee RecordCompensation Committee: Chair not stated; Members Diane Parks; Helen Collins; Mary T. Szela; Michael Vasconcelles
Committee AppointmentDiane Parks: member, Compensation Committee
Committee AppointmentHelen Collins: member, Compensation Committee
Committee AppointmentMary T. Szela: member, Compensation Committee
Committee AppointmentMichael Vasconcelles: member, Compensation Committee
Committee RecordNominating and Corporate Governance Committee: Chair not stated; Members Diane Parks; Helen Collins
Committee AppointmentDiane Parks: member, Nominating and Corporate Governance Committee
Committee AppointmentHelen Collins: member, Nominating and Corporate Governance Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerTroy E. Wilson, Ph.D., J.D., Chairman, President and Chief Executive Officer, from Apr 10, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingKURA (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 7, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameKura Oncology, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Francis Burrows, Ph.D.Chief Scientific Officercompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:16
- Mollie Leoni, M.D.Chief Medical Officercompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:19
- Teresa Bair, J.D.Chief Legal Officer and Secretarycompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:21
- Troy E. Wilson, Ph.D., J.D.Chairman, President and Chief Executive Officercompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:23
- Brian PowlChief Commercial Officer; Directorcompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:14, company:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:6
- Francis BurrowsChief Scientific Officercompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:15
- Kathleen FordChief Operating Officercompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:17
- Mollie LeoniChief Medical Officercompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:18
- Teresa BairChief Legal Officer and Secretarycompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:20
- Troy E. WilsonPresident and Chief Executive Officer; Chairman, President and Chief Executive Officercompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:22, company:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:5
- Diane ParksDirectorcompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:8
- Helen CollinsDirectorcompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:10
- Mary T. SzelaDirectorcompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:11
- Michael VasconcellesDirectorcompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:12
- Carol SchaferDirectorcompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:7
- Faheem HasnainLead Independent Directorcompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:9
- Thomas MalleyDirectorcompany:a0efacbe-524c-4f0c-8c09-118fc6401d00:leadership_role:13
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 8 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 7, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Apr 10, 2026. Retrieved Sep 6, 2026. Cited by 10 Claims.
- E3sec proxy. Published Apr 10, 2026. Retrieved Sep 2, 2026. Cited by 5 Claims.
- E4sec filing. Published Apr 10, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 10, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 10, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E7sec filing. Published Apr 10, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E8governance_people_committees. sec proxy. Cited by 10 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 7, 2026- Brian Powl seat on Kura Oncology, Inc., effective 2026-04-10.
- Michael Vasconcelles seat on Kura Oncology, Inc., effective 2026-04-10.
- Francis Burrows, Ph.D. executive of Kura Oncology, Inc., effective 2026-04-10.
- Mollie Leoni, M.D. executive of Kura Oncology, Inc., effective 2026-04-10.
- Teresa Bair, J.D. executive of Kura Oncology, Inc., effective 2026-04-10.
- Troy E. Wilson, Ph.D., J.D. executive of Kura Oncology, Inc., effective 2026-04-10.
- Helen Collins seat on Kura Oncology, Inc., effective 2021-01-01.
- Diane Parks seat on Kura Oncology, Inc., effective 2019-01-01.
- Mary T. Szela seat on Kura Oncology, Inc., effective 2018-01-01.